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background:  Body Mass Index (BMI) is a risk factor for atrial fibrillation (AF). Few studies have examined the relations between BMI and 
outcomes in patients with AF treated with different types of oral anticoagulation.
Methods:  The ARISTOTLE trial randomized 18,201 patients with AF to median 1.8 years treatment with apixaban or warfarin. Based 
on BMI kg/m2, 4246 patients were categorized normal (< 25), 6702 overweight (25-29) and 7159 obese (> 30). Outcomes were stroke/
systemic embolism, composite (stroke/systemic embolism, myocardial infarction or all-cause mortality), all-cause mortality and major 
bleeding. Multivariable models were used to estimate hazard ratios (HR) within BMI categories adjusting for established risk factors and 
study treatment. Significances of interactions were tested by continuous BMI and study treatment.
results:  (see figure): Patients assigned to apixaban had a lower risk for each outcome across the range of BMI without any significant 
treatment interaction. In multivariable analyses BMI was associated with lower mortality [overweight: HR 0.65 (95%CI 0.57-0.75); obese: 
HR 0.61 (0.52-0.71), p<0.0001], composite outcome [overweight: HR 0.72 (0.64-0.81); obese: HR 0.67 (0.58-0.76), p<0.0001] but not 
stroke nor major bleeding.
Conclusion:  In patients with AF, treatment with apixaban versus warfarin is associated with fewer strokes, lower mortality and less 
bleeding. In this population lower BMI is associated with higher event rates and higher mortality.
 
